Epoprostenol Sodium
61849-14-7CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)[O-])O[C@H]2C[C@H]1O.[Na+]LMHIPJMTZHDKEW-XQYLJSSYSA-MEpoprostenol Sodium is the sodium salt form of epoprostenol, a synthetic prostacyclin, a member of the family of prostaglandins, with vasodilatory and anticoagulant activity. Epoprostenol sodium directly simulates prostaglandin receptors in arterial vascular smooth muscle, thereby causing vasodilatation. This agent also inhibits platelet aggregation by antagonizing platelet glycoprotein (GP) IIb/IIIa receptors, thereby preventing thrombus formation.
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
化学的特性Epoprostenol is white crystalline powder
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H302 (97.4%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Epoprostenol sodium
Ambiguous-DILI-concern
7
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
用途薬理・生理作用研究用。
説明Epoprostenol is a naturally occurring prostaglandin indicated for the preservation of platelet function during cardiopulmonary bypass, prevention of platelet aggregation during charcoal hemoperfusion of patients in hepatic failure, and as an alternative to heparin during renal dialysis.
使用Epoprostenol is an Eicosanoid which prevents the formation of platelet plugs and is an effective vasodilator.
61849-14-7DTXSID3046617CHEMBL962